FDA's plan to boost cheaper copycat drugs could stall at patent office
Bullish
75.0
The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the opposite direction.
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
